Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRP-185 for idiopathic hypersomnia
ACTRN12625000555459Phase 2Withdrawn
- Sponsor
- Bioron Pharma
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupropion in hypersomnolence disorder, sponsored by Bioron Pharma. Primary endpoint: Change in excessive daytime sleepiness. Planned start Sep 2025; status: withdrawn.
02
Drugs
bupropion
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on ACTRN12625000555459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000555459.